A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2019
At a glance
- Drugs Darolutamide (Primary) ; Enzalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ODENZA Preference
- 05 Feb 2019 According to a Bayer media release, data from this trial will be presented at the 2019 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February 14-16 in San Francisco.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 25 Oct 2017 New trial record